BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

As biotechs look ahead to 2021, they may not see an end to the pandemic but they are optimistic that virtually all business activities will rebound to some extent, reflecting a net positive outlook. A...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

Cullinan’s $98.5 million series B round is another vote of confidence for the biotech holding company’s asset-centric pipeline management strategy that should bring its first four programs toward clinical proof of concept. Founding investors MPM...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among four additional...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
Items per page:
1 - 10 of 236
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jul 17, 2020
Finance

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

As biotechs look ahead to 2021, they may not see an end to the pandemic but they are optimistic that virtually all business activities will rebound to some extent, reflecting a net positive outlook. A...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals...
BioCentury | Jun 19, 2020
Management Tracks

Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more

Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

Cullinan’s $98.5 million series B round is another vote of confidence for the biotech holding company’s asset-centric pipeline management strategy that should bring its first four programs toward clinical proof of concept. Founding investors MPM...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among four additional...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
Items per page:
1 - 10 of 236